A limited sampling strategy for the estimation of 12-hour SangCya and Neoral AUCs in renal transplant recipients

Journal of Clinical Pharmacology

Volumn 39, Issue 2, 1999, Pages 166-171

  Meier Kriesche, Herwig Ulf ^d   Alloway, Rita ^a   Gaber, A Osama ^a   Canafax, Daniel M ^b   Kaplan, Bruce ^c  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b GENZYME CORPORATION   (United States)

^c SAINT BARNABAS MEDICAL CENTER   (United States)

^d Saint Barnabas Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG FORMULATION; HUMAN; KIDNEY TRANSPLANTATION; SAMPLING; STATISTICAL ANALYSIS;

AREA UNDER CURVE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LINEAR MODELS; PROSPECTIVE STUDIES;

EID: 0032937633     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007723     Document Type: Article

References (15)

1. Mueller EA, Kovarik JM, VanBree JB, Tetzloff W, Grevel J, Kutz K: Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharmaceutical Research 1994;11:301-304.
2. Kovarik JM, Mueller EA, VanBree JB, Tetzloff W, Kutz K: Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. Journal of Phamaceutical Sciences 1994;83:444-446.
3. Kovarik JM, Mueller EA, VanBree JB, Arns W, Renner E, Kutz K: Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994;16:232-237.
4. Klauser R, Irschik H, Kletzmayr J, et al: Neoral - a new microemulsion formula of cyclosporine A: interpatient pharmacokinetic variability in renal transplant recipients. Transplant Proc 1995;27:3427-3429.
5. Barone G, Chang CT, Choc MGJ, et al: The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal Allograft recipients. Transplantation 1996;61:875-880.
6. Schroeder TJ, First MR, Alloway RR, Canafax DM, Gaber AO, Gaston R: A series of comparative trials between Sang-35 and other cyclosporine formulations in stable renal transplant patients (abstract). Transplantation 1998;65(Suppl.):142.
7. Pan SH, Fisher RA, Lopez R, et al: Comparative pharmacokinetics of Sang-35 cyclosporine versus Neoral in stable adult liver transplant recipients (abstract). Transplantation 1998;65(Suppl.):89.
8. Canafax D, Alloway R, Schroeder TJ, Russell W, et al: Bioequivalence of Sang-35 and Neoral for cyclosporine metabolites in stable renal transplant recipients (abstract). Transplantation 1998;65 (Suppl.):82.
9. Johnston A, Kovarik JM, Mueller EA, Holt DW: Predicting patients' exposure to cyclosporine. Transpl Int 1996;9(Suppl. 1):S305-S307.
10. Amante AJ, Kahan BD: Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate post-transplant period. Transplant Proc 1996;28:2162-2163.
11. Johnston A, Sketris I, Marsden JT, et al: A limited sampling strategy for the measurement of cyclosporine AUG. Transplant Proc 1990;22:1345-1346.
12. Grevel J, Kahan BD: Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem 1991;37:1905-1908.
13. Gaspari F, Ruggenenti P, Torre L, Bertocchi C, Remuzzi G, Perico N: Failure to predict cyclosporine area under the curve using a limited sampling strategy. Kidney Int 1993;44:436-439.
14. Charlebois JE, Lum BL, Cooney GF, Mochon M, Kaiser BA: Comparison and validation of limited sampling equations for cyclosporine area-under-the-curve monitoring calculations in pediatric renal transplant recipients. Ther Drug Monit 1997;19:277-280.
15. Wu G: An explanation for failure to predict cyclosporine area under the curve using a limited sampling strategy: a beginner's second note. Pharmacol Res 1997;35:547-552.